SCHEMBL3622367

SCHEMBL3622367

O=C(NCCN1CCOCC1)OCc1cccc(Br)c1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.53
RXFP1 Q9HBX9 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
ALDH1A1 P00352 1/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
GLA P06280 1/20 0.47
HPGD P15428 1/20 0.47
ABL1 P00519 1/20 0.47
RIN1 Q13671 1/20 0.47
HSD17B10 Q99714 1/20 0.47
LMNA P02545 2/20 0.47
CARM1 Q86X55 1/20 0.47
PRMT6 Q96LA8 1/20 0.47
MAPK1 P28482 1/20 0.46
MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6044214 0.86 MEN1 (0.57) KMT2AALDH1A1HTTSMN1; SMN2HPGD
SCHEMBL30899745 0.84 MEN1 (0.58) KMT2AALDH1A1HTTSMN1; SMN2HPGD
SCHEMBL1463825 0.78 POLB (0.61) KMT2AALDH1A1HTTSMN1; SMN2LMNA
SCHEMBL7159219 0.76 LMNA (0.63) KMT2AALDH1A1HTTSMN1; SMN2LMNA
SCHEMBL4243253 0.75 L3MBTL1 (0.53) KMT2ACYP2C19ALDH1A1LMNACARM1
SCHEMBL13735763 0.75 HTT (0.59) KMT2ACYP2C19HTTSMN1; SMN2GLA
SCHEMBL102359 0.75 ALDH1A1 (0.52) KMT2ARXFP1CYP2C9CYP2C19ALDH1A1
SCHEMBL10242970 0.73 GLA (0.54) KMT2ACYP2C19GLAMAPK1
SCHEMBL5256343 0.73 SIGMAR1 (0.58) KMT2AALDH1A1HTTSMN1; SMN2
SCHEMBL20718021 0.73 SMN1; SMN2 (0.58) KMT2AALDH1A1HTTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470850-B2 Inhibitors of VEGF receptor and HGF receptor signalling METHYLGENE INC. (CA) 2013-06-25 US disclosed
US-20100216766-A1 Inhibitors of VEGF Receptor and HGF Receptor Signalling 92229129 QUEBEC INC. (CA) 2010-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216766-A1 Inhibitors of VEGF Receptor and HGF Receptor Signalling HGF, MET, FLT1 KMT2A 3438/4885RXFP1 1080/4885CYP2C9 4745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.